A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
- Registration Number
- NCT05518149
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor \[SSRI\] or serotonin and norepinephrine reuptake inhibitor \[SNRI\]) in all participants with major depressive disorder (MDD).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 840
Transferred-entry participants:
-Participants must have completed the double blind (DB) (expand DB) Treatment Phase of Study 67953964MDD3001 or Study 67953964MDD3002 without early treatment discontinuation or switch in the oral selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) in the parent study
Direct-entry participants:
- Have a Hamilton Depression Rating Scale (HDRS)-17 total score of 20 or higher at the first and second screening interviews and must not demonstrate a clinically significant improvement (that is, an improvement of more than 20 percent (%) on their HDRS-17 total score) between the first and the second independent HDRS-17 assessments
- Have had an inadequate response to at least 1 oral antidepressant treatment, administered at an adequate dose (at or above the minimum therapeutic dose per Massachusetts general hospital antidepressant treatment response questionnaire [MGH ATRQ]) and duration (at least 6 weeks) in the current episode of depression
- Must be an outpatient at open-label treatment phase baseline
- Meet Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) diagnostic criteria for recurrent or single episode major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Structured Clinical Interview for DSM-5 Axis I Disorders-Clinical Trials Version (SCID-CT)
Direct-entry and Transferred-entry Participants:
-Participants should not take any prohibited medication or food supplements
Transferred-entry Participants:
- Participant has been non-compliant with the study intervention administration in the DB Treatment Phase in either of Studies 67953964MDD3001 or 67953964MDD3002 (that is, have missed either 4 or more consecutive doses of study intervention or a total of 8 or more doses during the DB Treatment Phase)
- Participant has any condition or situation/circumstance for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being) or that could prevent, limit, or confound the protocol specified assessments
Direct-entry Participants:
- Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator
- Has a history or evidence of clinically meaningful noncompliance with current antidepressant therapy
- Known allergies, hypersensitivity, or intolerance to aticaprant or any of its excipients
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Aticaprant 10 mg Aticaprant Participants will enter this study directly or after completing double-blind phase of studies 67953964MDD3001 or 67953964MDD3002 and will receive Aticaprant 10 milligrams (mg), once daily, orally in addition to the current antidepressant selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) therapy on Day 1 up to 52 weeks.
- Primary Outcome Measures
Name Time Method Withdrawal Symptoms Assessment Using the Physician Withdrawal Checklist (PWC-20) Up to Week 54 Withdrawal symptoms are assessed using the PWC-20. The PWC-20 is a simple and accurate method used to assess potential withdrawal symptoms following cessation of treatment. The PWC-20 is a reliable and sensitive instrument for the assessment of discontinuation symptoms.
Number of Participants with Adverse Events (AEs) Up to Week 54 An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.
Number of Participants with Abnormal Body Mass Index (BMI) Up to Week 54 A BMI between 18.5 and 25 kilogram per meter square (kg/m\^2) indicates a normal weight.
Number of Participants with Abnormalities in Clinical Laboratory parameters Up to Week 54 Number of participants with abnormalities in clinical laboratory parameters will be reported.
Number of participants with Clinically Relevant Sexual Dysfunction Over Time as Measured by the Arizona Sexual Experiences Scale (ASEX) Score Up to Week 54 The ASEX is a participant-reported five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point scale, ranging from 1 to 6. Total score ranges from 5 to 30, with the higher scores indicating more sexual dysfunction.
Number of Participants with Adverse Events of Special Interest (AESI) Up to Week 54 AEs considered to be of special interest are as Pruritus and Diarrhea.
Number of Participants with Abnormal Body Weight Up to Week 54 Participants will be weighed at approximately the same time of day on the same scale, wearing lightweight clothing without shoes; they will be instructed to empty their bladders before being weighed.
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS) Up to Week 54 C-SSRS is semi structured clinician-administered questionnaire designed to solicit the occurrence, severity, and frequency of suicide-related ideation and behaviors. The maximum score assigned for each participant will also be summarized into one of three categories: no suicidal ideation or behavior (0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranges from 1 to 10. Higher scores indicate greater severity.
Number of Participants with Change from Baseline in Vital Signs Abnormalities Up to Week 54 Vital signs include body weight, temperature, pulse/heart rate, respiratory rate, pulse oximetry and blood pressure (systolic and diastolic) values.
Number of Participants with Abnormalities in Electrocardiogram (ECG) Up to Week 54 Number of participants with abnormalities in ECG will be reported.
- Secondary Outcome Measures
Name Time Method Change from Baseline in the Montgomery-asberg Depression Rating Scale (MADRS) Total Score Over Time Baseline up to Week 54 Change from baseline in MADRS total score over time will be reported. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
Change from Baseline in the Participant Health Questionnaire, 9-Item (PHQ-9) Total Score over Time Baseline up to Week 54 Change from baseline in PHQ-9 total score over time will be reported. The 9-item PHQ-9 scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) diagnostic criteria for recurrent or single episode major depressive disorder (MDD) criteria and used both as a screening tool and a measure of response to treatment for depression. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms.
Change from Baseline in Dimensional Anhedonia Rating Scale (DARS) Total Score Over Time Baseline up to Week 54 Change from baseline in DARS total score over time will be reported. The DARS is a 17-item self-report questionnaire that is designed to assess anhedonia in MDD, and particularly to increase scale generalizability while maintaining specificity. Respondents provide their own examples of rewarding experiences across the domains of hobbies, social activities, food/drink, and sensory experience. Participants answer a set of standardized questions about desire, motivation, effort and consummatory pleasure with a recall period of "right now" for the examples provided. The instrument is scored as a total sum of all items (range 0-68) with higher scores reflecting increased motivation, effort and pleasure (that is, less anhedonia).
Change from Baseline in the Clinical Global Impression-Severity (CGI-S) Total Score Over Time Baseline up to Week 54 Change from baseline in the CGI-S total score over time will be reported. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. The CGI-S permits a global evaluation of the participant's condition at a given time.
Percentage of Participants with Greater than or Equal to (>=) 50 percent (%) Reduction from Baseline in the MADRS Total Score Over Time Week 54 Percentage of participants with \>=50% reduction from baseline in the MADRS total score over time will be reported. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
Percentage of Participants with Remission of Depressive Symptoms Over Time Week 54 Percentage of participants with remission of depressive symptoms over time, defined as a MADRS total score less than or equal to (\<=) 10 will be reported. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
Trial Locations
- Locations (224)
University of Alabama at Birmingham - The Kirklin Clinic
🇺🇸Birmingham, Alabama, United States
SW Biomedical Research LLC
🇺🇸Tucson, Arizona, United States
University of Arizona
🇺🇸Tucson, Arizona, United States
Advanced Research Center Inc
🇺🇸Anaheim, California, United States
Proscience Research Group
🇺🇸Culver City, California, United States
Behavioral Research Specialists LLC
🇺🇸Glendale, California, United States
Sunwise Clinical Research
🇺🇸Lafayette, California, United States
Asclepes Research
🇺🇸Long Beach, California, United States
Excell Research Inc
🇺🇸Oceanside, California, United States
Pacific Neuropsychiatric Specialists
🇺🇸Orange, California, United States
Prospective Research Innovations Inc
🇺🇸Rancho Cucamonga, California, United States
University of California San Diego Medical Center
🇺🇸San Diego, California, United States
Syrentis Clinical Research
🇺🇸Santa Ana, California, United States
CMB Clinical Trials
🇺🇸Santee, California, United States
California Neuroscience Research
🇺🇸Sherman Oaks, California, United States
Viking Clinical Research Ltd
🇺🇸Temecula, California, United States
Sarkis Clinical Trials
🇺🇸Gainesville, Florida, United States
Galiz Research
🇺🇸Hialeah, Florida, United States
Vertex Clinical Research
🇺🇸Maitland, Florida, United States
Meridian International Research
🇺🇸Miami Gardens, Florida, United States
University of Miami
🇺🇸Miami Lakes, Florida, United States
Pacific Clinical Research Medical Group
🇺🇸Upland, California, United States
Next Level Clinical Trials, LLC
🇺🇸West Covina, California, United States
University of Connecticut Health Center
🇺🇸Farmington, Connecticut, United States
Gulfcoast Medical Research Center
🇺🇸Fort Myers, Florida, United States
Amedica Research Institute Inc
🇺🇸Hialeah, Florida, United States
Global Medical Institutes
🇺🇸Miami, Florida, United States
LCC Medical Research Institute Inc
🇺🇸Miami, Florida, United States
MCB Clinical Research Centers LLC
🇺🇸Colorado Springs, Colorado, United States
Innovative Research of West Florida, Incorporated
🇺🇸Clearwater, Florida, United States
CNS Clinical Research Group
🇺🇸Coral Springs, Florida, United States
New Life Medical Research Center, Inc.
🇺🇸Hialeah, Florida, United States
Vital Care Research
🇺🇸Miami, Florida, United States
Pharmax Research Clinic Inc
🇺🇸Miami, Florida, United States
Florida Research Center Inc.
🇺🇸Miami, Florida, United States
A Plus Research
🇺🇸Miami, Florida, United States
Ezy Medical Research
🇺🇸Miami, Florida, United States
Felicidad Medical Research
🇺🇸Miami, Florida, United States
Bravo Health Care Center
🇺🇸North Bay Village, Florida, United States
K2 Medical Research
🇺🇸Ocoee, Florida, United States
Medical Research Group of Central Florida
🇺🇸Orange City, Florida, United States
APG Research LLC
🇺🇸Orlando, Florida, United States
Combined Research Orlando
🇺🇸Orlando, Florida, United States
Quantum Laboratories
🇺🇸Pompano Beach, Florida, United States
CDC Research Institute LLC
🇺🇸Port Saint Lucie, Florida, United States
USF, Department of Psychiatry and Behavioral Neurosciences
🇺🇸Tampa, Florida, United States
Research Network America
🇺🇸Berwyn, Illinois, United States
Chicago Research Center
🇺🇸Chicago, Illinois, United States
Revive Research Institute
🇺🇸Elgin, Illinois, United States
Psychiatric Medicine Associates LLC
🇺🇸Skokie, Illinois, United States
Tandem Clinical Research
🇺🇸Marrero, Louisiana, United States
Clinical Trials of America
🇺🇸Monroe, Louisiana, United States
CBH Health
🇺🇸Gaithersburg, Maryland, United States
ActivMed Practices and Research
🇺🇸Methuen, Massachusetts, United States
Michigan Clinical Research Institute
🇺🇸Ann Arbor, Michigan, United States
Psychiatric Care and Research Center (PCRC)
🇺🇸O'Fallon, Missouri, United States
Midwest Research Group
🇺🇸Saint Charles, Missouri, United States
Montefiore Medical Center PRIME
🇺🇸Bronx, New York, United States
Erie County Medical Center
🇺🇸Buffalo, New York, United States
Bioscience Research LLC
🇺🇸Mount Kisco, New York, United States
Manhattan Behavioral Medicine
🇺🇸New York, New York, United States
Fieve Clinical Research Inc
🇺🇸New York, New York, United States
Finger Lakes Clinical Research
🇺🇸Rochester, New York, United States
New Hope Clinical Research
🇺🇸Charlotte, North Carolina, United States
Monroe Biomedical Research
🇺🇸Monroe, North Carolina, United States
Patient Priority Clinical Sites LLC
🇺🇸Cincinnati, Ohio, United States
University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
🇺🇸Cincinnati, Ohio, United States
Wexner Medical Center at the Ohio State University
🇺🇸Columbus, Ohio, United States
Midwest Clinical Research Center
🇺🇸Dayton, Ohio, United States
Charak Center for Health and Wellness
🇺🇸Garfield Heights, Ohio, United States
Conrad Clinical Research
🇺🇸Edmond, Oklahoma, United States
Sooner Clinical Research
🇺🇸Oklahoma City, Oklahoma, United States
Paradigm Research Professionals, LLC
🇺🇸Oklahoma City, Oklahoma, United States
Lehigh Center for Clinical Research LLC
🇺🇸Allentown, Pennsylvania, United States
Suburban Research Associates
🇺🇸Media, Pennsylvania, United States
University of Pennsylvania - Perelman School of Medicine
🇺🇸Philadelphia, Pennsylvania, United States
Austin Clinical Trial Partners
🇺🇸Austin, Texas, United States
West Houston Clinical Research Service
🇺🇸Bellaire, Texas, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
North Texas Clinical Trials
🇺🇸Fort Worth, Texas, United States
R and H Clinical Research
🇺🇸Katy, Texas, United States
Alpine Research Organization
🇺🇸Clinton, Utah, United States
Cedar Psychiatry
🇺🇸Murray, Utah, United States
University of Virginia
🇺🇸Charlottesville, Virginia, United States
Northwest Clinical Research Center
🇺🇸Bellevue, Washington, United States
INSA Instituto de Neurociencias San Agustín
🇦🇷Buenos Aires, Argentina
CENydET - Centro Neurobiologico y de Stress Traumatico
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
STAT Research S A
🇦🇷Ciudad Autonoma de Buenos Aires, Argentina
CIPREC
🇦🇷Ciudad Autonoma de Buenos Aires, Argentina
Hospital Italiano de Buenos Aires
🇦🇷Ciudad Autonoma de Buenos Aires, Argentina
Resolution
🇦🇷Ciudad de Mendoza, Argentina
CEN Consultorios Especializados en Neurociencias
🇦🇷Cordoba, Argentina
Fundacion Lennox
🇦🇷Cordoba, Argentina
Centro Medico Luquez
🇦🇷Cordoba, Argentina
Instituto Medico DAMIC
🇦🇷Córdoba, Argentina
CENPIA
🇦🇷La Plata, Argentina
Clinica Privada de Salud Mental Santa Teresa de Ávila
🇦🇷La Plata, Argentina
C I A P Centro de investigacion y Asistencia en Psiquiatria
🇦🇷Rosario, Argentina
Instituto Medico de La Fundacion Estudios Clinicos
🇦🇷Rosario, Argentina
Clinica Mayo de UMCB
🇦🇷San Miguel de Tucuman, Argentina
Clinica El Jardin
🇦🇷Santiago del Estero, Argentina
Peninsula Therapeutic & Research Group
🇦🇺Frankston, Australia
Albert Road Clinic
🇦🇺Melbourne, Australia
The Alfred Hospital
🇦🇺Melbourne, Australia
Anima
🇧🇪Alken, Belgium
C.H.U. Brugmann
🇧🇪Bruxelles, Belgium
Pz Duffel
🇧🇪Duffel, Belgium
Vitaz
🇧🇪Sint Niklaas, Belgium
Trial Tech Tecnologia em Pesquisas com Medicamentos
🇧🇷Curitiba, Brazil
Universidade Federal do Ceara Hospital Universitario Walter Cantidio
🇧🇷Fortaleza, Brazil
Instituto Goiano de Neuropsiquiatria
🇧🇷Goiania, Brazil
Associacao Hospitalar Moinhos de Vento
🇧🇷Porto Alegre, Brazil
NPCRS Nucleo de Pesquisa Clinica do Rio Grande do Sul
🇧🇷Porto Alegre, Brazil
Ruschel Medicina e Pesquisa Clínica Ltda
🇧🇷Rio de Janeiro, Brazil
CEMEC - Centro Multidisciplinar de Estudos Clínicos
🇧🇷Sao Bernardo, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
🇧🇷Sao Jose do Rio Preto, Brazil
BR Trials
🇧🇷Sao Paulo, Brazil
CPQuali Pesquisa Clinica LTDA ME
🇧🇷São Paulo, Brazil
Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET
🇧🇬Cherven Bryag, Bulgaria
Ambulatory Group practice for specialized help in psychiary Philipopolis ODD
🇧🇬Plovdiv, Bulgaria
Medical Center Mentalcare OOD
🇧🇬Plovdiv, Bulgaria
Mental Health Center - Rousse
🇧🇬Ruse, Bulgaria
Medical Center St. Naum
🇧🇬Sofia, Bulgaria
MHC - Sofia, EOOD
🇧🇬Sofia, Bulgaria
DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD
🇧🇬Sofia, Bulgaria
Medical Center Hera EOOD
🇧🇬Sofia, Bulgaria
Medical Center Intermedica, OOD
🇧🇬Sofia, Bulgaria
Diagnostic Consulting Center Mladost - M Varna
🇧🇬Varna, Bulgaria
Mental Health Center - Veliko Tarnovo EOOD
🇧🇬Veliko Tarnovo, Bulgaria
DIEX Recherche Sherbrooke Inc
🇨🇦Sherbrooke, Quebec, Canada
Hebei Mental Health Center
🇨🇳Baoding, China
Beijing Anding Hospital of Capital Medical University
🇨🇳Beijing, China
Peking University Sixth Hospital
🇨🇳Beijing, China
Beijing Huilongguan Hospital
🇨🇳Beijing, China
West China Hospital Sichuan University
🇨🇳Chengdu, China
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, China
Shanghai Mental Health Center
🇨🇳Shanghai, China
Tongji Hospital of Tongji University
🇨🇳Shanghai, China
The First Hospital of Hebei Medical University
🇨🇳Shijiazhuang, China
Tianjin Anding Hospital
🇨🇳Tianjin, China
Wuhan Mental Health Center
🇨🇳Wuhan, China
Wuhu Hospital of Beijing Anding hospital
🇨🇳Wuhu, China
XiAn Mental Healthcare Center
🇨🇳XI An, China
Psychiatricka ambulance, MUDr. Marta Holanova
🇨🇿Brno, Czechia
Narodni ustav dusevniho zdravi
🇨🇿Klecany, Czechia
Neuroterapie KH S R O
🇨🇿Kutna Hora, Czechia
A Shine S R O
🇨🇿Plzen, Czechia
Praglandia s r o
🇨🇿Prague 5, Czechia
Clintrial s r o
🇨🇿Praha 10, Czechia
AD71 s.r.o.
🇨🇿Praha 10, Czechia
NeuropsychiatrieHK, s.r.o.
🇨🇿Praha 6, Czechia
Medical Services Prague S R O
🇨🇿Praha 6, Czechia
Institut Neuropsychiatricke pece
🇨🇿Praha 8, Czechia
Psychiatricka ordinace
🇨🇿Usti nad Labem, Czechia
CHU de Brest - Hopital de la Cavale Blanche
🇫🇷Bohars, France
CHU Clermont-Ferrand - Hopital Gabriel Montpied
🇫🇷Clermont Ferrand, France
Cabinet Medical des Drs Prizac-Desbonnet Scottez
🇫🇷Douai, France
CHU de Nantes hotel Dieu
🇫🇷Nantes, France
Hopital Sainte Anne
🇫🇷Paris, France
CHRU de Tours Clinique Psychiatrique Universitaire
🇫🇷Tours cedex 9, France
Obudai Egeszsegugyi Centrum Kft
🇭🇺Budapest, Hungary
Semmelweis Egyetem
🇭🇺Budapest, Hungary
Bugat Pal Korhaz
🇭🇺Gyongyos, Hungary
Dr Mathe es Tarsa Bt
🇭🇺Kalocsa, Hungary
PsychoTech Kft
🇭🇺Pecs, Hungary
Tolna Megyei Balassa Janos Korhaz
🇭🇺Szekszárd, Hungary
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
🇮🇹Bergamo, Italy
Azienda Ospedaliero Universitaria Mater Domini
🇮🇹Catanzaro, Italy
AUSL LE di Lecce
🇮🇹Lecce, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
🇮🇹Milano, Italy
ASST Fatebenefratelli Sacco
🇮🇹Milano, Italy
Ospedale San Raffaele
🇮🇹Milano, Italy
Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte
🇮🇹Siena, Italy
The Catholic University Of Korea St Mary'S Hospital
🇰🇷Bucheon, Korea, Republic of
Inje University Haeundae Paik Hospital
🇰🇷Busan, Korea, Republic of
Korea University Ansan Hospital
🇰🇷Gyeonggi-do, Korea, Republic of
Kyung Hee University Medical Center
🇰🇷Seoul, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea Yeouido St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk
🇵🇱Bialystok, Poland
Clinsante Osrodek Badan Klinicznych
🇵🇱Bydgoszcz, Poland
Centrum Badan Klinicznych PI House sp z o o
🇵🇱Gdansk, Poland
Centrum Medyczne Care Clinic Katowice
🇵🇱Katowice, Poland
Specjalistyczna Indywidualna Praktyka Lekarska
🇵🇱Lodz, Poland
Filip Rybakowski Specjalistyczna Praktyka Lekarska
🇵🇱Poznan, Poland
Indywidualna Specjalistyczna Praktyka Lekarska Agnieszka Remlinger Molenda
🇵🇱Suchy Las, Poland
Specjalistyczny Gabinet Psychiatryczny Kowalkowski Gerard
🇵🇱Torun, Poland
Hospital de Braga
🇵🇹Braga, Portugal
Hospital CUF Inf. Santo
🇵🇹Lisboa, Portugal
Fund. Champalimaud
🇵🇹Lisboa, Portugal
Psychomed-Svatosavsky, s.r.o.
🇸🇰Banska Bystrica, Slovakia
Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach
🇸🇰Bojnice, Slovakia
Psychiatricka Ambulancia Mentum S.R.O.
🇸🇰Bratislava, Slovakia
Epamed sro
🇸🇰Koshice, Slovakia
Univerzitna nemocnica L. Pasteura Kosice
🇸🇰Kosice, Slovakia
Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
🇸🇰Liptovsky Mikulas, Slovakia
Psychiatricka Ambulancia Psycholine S.R.O.
🇸🇰Rimavska Sobota, Slovakia
Crystal Comfort s.r.o.
🇸🇰Vranov nad Toplou, Slovakia
Cape Town Clinical Research Centre
🇿🇦Cape Town, South Africa
Gert Bosch Pretoria South Africa
🇿🇦Pretoria, South Africa
Somerset West Clinical Research Unit
🇿🇦Strand, South Africa
Institucion Hosp Hestia Palau
🇪🇸Barcelona, Spain
Hosp Univ Vall D Hebron
🇪🇸Barcelona, Spain
Hosp Clinic de Barcelona
🇪🇸Barcelona, Spain
Hosp. Univ. La Paz
🇪🇸Madrid, Spain
Hosp Regional Univ de Malaga
🇪🇸Málaga, Spain
Hosp. Univ. Son Espases
🇪🇸Palma de Mallorca, Spain
Hosp. El Bierzo
🇪🇸Ponferrada, Spain
Corporacio Sanitari Parc Tauli
🇪🇸Sabadell, Spain
Hosp. Alvaro Cunqueiro
🇪🇸Vigo, Spain
Hosp. Psiquiatrico Alava
🇪🇸Vitoria, Spain
Sahlgrenska Universitetssjukhuset
🇸🇪Goteborg, Sweden
ProbarE i Lund AB
🇸🇪Lund, Sweden
ProbarE i Stockholm AB
🇸🇪Stockholm, Sweden
Studieenheten Akademiskt Specialistcentrum Stockholm
🇸🇪Stockholm, Sweden
China Medical University Hospital
🇨🇳Taichung, Taiwan
Taipei Medical University
🇨🇳Taipei City, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Cheng Hsin General Hospital
🇨🇳Taipei, Taiwan
Institute of Psychiatry
🇬🇧London, United Kingdom
Moorgreen Hospital
🇬🇧Southampton, United Kingdom